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ABSTRACT
Objective: To investigate the cost-effectiveness of a
hypothetical cardioprotective agent used to reduce
infarct size in patients undergoing percutaneous
coronary intervention (PCI) after anterior ST-elevation
myocardial infarction.
Methods: Design: A cost-utility analysis using a
Markov model. Setting: The National Health Service in
the UK. Patients: Patients undergoing PCI after anterior
ST-elevation myocardial infarction. Interventions: A
cardioprotective agent given at the time of reperfusion
compared to no cardioprotection. We assumed the
cardioprotective agent (given at the time of
reperfusion) would reduce the risk and severity of
heart failure (HF) after PCI and the risk of mortality
after PCI (with a relative risk ranging from 0.6 to 1).
The costs of the cardioprotective agent were assumed
to be in the range £1000–4000. Main outcome
measures: The incremental costs per quality-adjusted
life-year (QALY) gained, using 95% CIs from 1000
simulations.
Results: Incremental costs ranged from £933 to
£3820 and incremental QALYs from 0.04 to 0.38. The
incremental cost-effectiveness ratio (ICER) ranged from
£3311 to £63 480 per QALY gained. The results were
highly dependent on the costs of a cardioprotective
agent, patient age, and the relative risk of HF after PCI.
The ICER was below the willingness-to-pay threshold
of £20 000 per QALY gained in 71% of the
simulations.
Conclusions: A cardioprotective agent that can reduce
the risk of HF and mortality after PCI has a high
chance of being cost-effective. This chance depends on
the price of the agent, the age of the patient and the
relative risk of HF after PCI.
INTRODUCTION
Acute myocardial infarction (AMI) is a major
cause of mortality and morbidity, even with
the use of early reperfusion strategies such as
percutaneous coronary intervention (PCI).
In case of AMI, a coronary artery becomes
occluded, causing myocardial ischaemia,
which in its turn causes myocardial necrosis.
The extent of this necrosis, the infarct size, is
a major determinant of mortality and mor-
bidity after AMI. After AMI blood flow in the
ischaemic myocardium should therefore be
restored as soon as possible to minimise
infarct size and associated complications. PCI
is frequently used to accomplish this but, may
itself cause injury to the myocardium as a
consequence of the restoration in blood flow
with generation of oxidative stress. The effi-
cacy of reperfusion therapy is often assessed
by measuring the infarct size using serum
markers or MRI. Cardioprotection could be
used at the time of reperfusion to reduce
reperfusion injury and further decrease myo-
cardial necrosis. Cardioprotection can be
defined as any strategy to preserve the heart
by reducing or even preventing myocardial
damage.1 Many cardioprotective strategies
Strengths and limitations of this study
▪ A strength of this study is that a model is pre-
sented that can be used for any potential cardio-
protective agent to study the economic
consequences of implementing this agent in clin-
ical practice. If the effect of the new drug on the
incidence of heart failure after PCI is known, this
model can be updated to present a more precise
estimate of the cost-effectiveness of this drug.
▪ The main limitation of this study is that it is
based on a hypothetical drug. There are currently
not enough data available on the long-term
effectiveness of any of the potential cardioprotec-
tive agents.
▪ We also assumed that the cardioprotective agent
would only reduce the risk and severity of heart
failure and not the risk of other clinical major
adverse cardiac events, such as recurrent infarc-
tion. In reality, a cardioprotective agent might
have an effect on all such events. However, by
only taking into account heart failure risk we
present a conservative estimate of the cost-
effectiveness. A cardioprotective agent that will
also decrease the risk of other major adverse
cardiac events is expected to have a higher
chance to be cost-effective.
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have been developed and tested to reduce reperfusion
injury and decrease infarct size.2–4 These include post-
conditioning, remote ischaemic conditioning, intraven-
ous cooling and various pharmacological agents. None
of these strategies has yet translated into clinical practice;
some did not have the desired effect in clinical trials
while others are still in development.2–4
The longer term consequences of AMI are not only
caused by the direct structural damage inflicted by the
infarction, but also by secondary changes in the size and
shape of the myocardium (ventricular remodelling).
This can lead to ventricular dysfunction with subsequent
heart failure (HF), long-term morbidity and a shortened
lifespan.5 6 By reducing infarct size, cardioprotective
agents potentially decrease the incidence and severity of
HF after AMI, thereby reducing long-term morbidity
which might carry significant economic consequences.
Such consequences have not yet been studied. The aim
of this study is to investigate the cost-effectiveness of a
hypothetical cardioprotective agent used to reduce
infarct size in patients undergoing PCI after anterior
ST-elevation myocardial infarction (STEMI).
METHODS
Model structure
A Markov model was developed to assess the potential
clinical effect and the economic consequences of a cardi-
oprotective agent. It is expected that a reduced infarct
size will affect the risk and severity of HF after STEMI. We
conservatively assumed that the cardioprotective agent
would only reduce the risk and severity of HF and not the
risk of other clinical major adverse cardiac events, such as
recurrent infarction. Figure 1 depicts the different health
states in the Markov model. After PCI a patient could stay
alive without HF, develop HF (in any of the four
New York Heart Association (NYHA) classes) or die.
Other than death, which is an absorbing state, patients
either stay in their health state or move to another state
in monthly cycles. In the model, patients are unable to
recover from having HF, but could move up and down
between the different NYHA classes or stay without symp-
toms (NYHA class 1). Patients who did not have HF dir-
ectly after PCI may develop HF later. Transitions in any
cycle were dependent on time since the start of the
model, but not on what happened prior to that cycle
(past health states or how long they have been in a par-
ticular state).The model was run over a lifetime horizon.
Clinical input
Natural disease history
A literature search was performed to collect relevant
data to populate the model. In our base case, patients
were 65 years old when having PCI. Clinical outcome
after PCI varies among different patient groups.
Mortality after PCI has been reported between 3.4%7 to
7.8%,8 and the incidence of HF from 5%9 to almost
30%.10 11 We assumed that mortality after PCI would be
3.4% and the incidence of HF 10%. Late onset HF
would occur in 5% of patients in the first month after
PCI, and a further 0.5% until 2 years after PCI.9 11
Clinical input parameters are shown in table 1.
Transition probabilities between the different NYHA
classes were derived from a randomised trial12 as in pre-
vious cost-effectiveness studies of HF treatment13 14
(table 2). Age-specific long-term mortality data of myo-
cardial infarction patients were used to determine the
mortality of patients in the ‘No HF’ or ‘NYHA class I’
state.15 This was done by applying monthly transition
probabilities for mortality to all survivors of the previous
month. An excess mortality risk was applied to patients
in the NYHA class II to IV states (0.26–0.72% if not hos-
pitalised, 1.09–5.33% if hospitalised, see table 1). These
data, as well as the probability of hospitalisation in the
different NYHA classes, were derived from a cost-
effectiveness study on the treatment of HF.13
Efficacy of hypothetical cardioprotective agent
As the analysis is based on a hypothetical cardioprotec-
tive agent, no data on effectiveness were currently avail-
able for use in this model. We assumed that the drug
would affect the incidence of HF and mortality directly
after PCI, as well as the incidence of new HF or worsen-
ing of existing HF in the 6 months following PCI. In pre-
vious studies on the effectiveness of cardioprotective
strategies, varying results were found. In a study on the
efficacy of adenosine in AMI it was found that 1 month
mortality was reduced from 9.2% to 5.2% (p=0.014) and
6-month mortality was reduced from 11.2% to 7.3% in
patients receiving early reperfusion.21 A small reduction
in in-hospital HF was seen, although this was not statistic-
ally significant (3.2% vs 4.0%, p=0.59). A larger reduc-
tion in HF was seen for ischaemic postconditioning in
patients treated with PCI (27% vs 46%, p=0.048).22 In
the current study we therefore assumed a relative risk of
these events in the intervention group in the range of
60–100% (point estimate 80%).
Figure 1 Health states in the Markov model. After PCI,
patients could move to any of the health states (light grey
arrows). In subsequent cycles, patients could stay in the
health state or move to another health state (dark grey
arrows). In the model, patients are unable to recover from
having HF, but could move up and down between the different
NYHA classes or stay without symptoms (NYHA class 1).
Patients who did not have HF directly after PCI may develop
HF later. HF, heart failure; NYHA, New York Heart
Association; PCI, percutaneous coronary intervention.
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Health utility
The health utility after PCI, without HF, was 0.86 in our
model based on results from the EuroQol Questionnaire
as in previous studies.16 23 Patients with HF had a lower
quality of life, depending on the severity of the disease,
varying from 0.82 in NYHA class I to 0.51 in NYHA class
IV.13 14 When a patient was hospitalised, a temporary
decrement of 0.10 was applied in the month following
hospitalisation.13 14
Costs
The perspective of this cost-effectiveness analysis was the
cost to the National Health Service (NHS). Costs of
AMI, PCI and HF events were derived from the NHS
Table 1 Input parameters
Parameter Base case value Lower limit Upper limit Distribution Source
Age (years) 65 55.00* 75.00* Normal (μ:65, SD: 5) Assumption
Probabilities without intervention
Outcome after PCI
Heart failure 10.00% 7.38%† 12.62%† Dirichlet‡ (50, 17, 434) 9–11
Mortality 3.39% 1.81%† 4.98%† 7
Percentage of heart failure patients in each NYHA class
NYHA I 23.00% 16.17%† 29.83%† Dirichlet‡ (34, 71, 32, 7) 9
NYHA II 50.00% 41.89%† 58.11%† 9
NYHA III 22.00% 15.28%† 28.72%† 9
NYHA IV 5.00% 1.46%† 8.54%† 9
New onset HF, monthly probability
First month 5.00% 0.00%* 10.00%* β (α: 3.8, β: 71.3) 9, 11
Month 2–24 0.02% 0.00%* 0.04%* β (α: 4.3, β: 20 824) 9
After 24 months 0.00% Assumption
RR with cardioprotection compared to no cardioprotection
Heart failure after PCI 80% 60.00%* 100.00%* Uniform (0.6–1) Assumption
Mortality after PCI 80% 60.00%* 100.00%* Uniform (0.6–1) Assumption
Develop new HF, first 6 months 80% 60.00%* 100.00%* Uniform (0.6–1) Assumption
Worsening HF, first 6 months 80% 60.00%* 100.00%* Uniform (0.6–1) Assumption
Probability of hospitalisation (per month)
NYHA I 1.52% 0.03%* 3.01%* β (α: 3.9, β: 254.4) 13
NYHA II 2.40% 0.05%* 4.75%* β (α: 3.9, β: 157.9) 13
NYHA III 2.40% 0.05%* 4.75%* β (α: 3.9, β: 157.9) 13
NYHA IV 15.40% 0.31%* 30.49%* β (α: 3.2, β: 17.8) 13
Excess mortality (per month)
When hospitalised class II 1.09% 0.08%† 2.23%† β (α: 4.0, β: 396) 13
When not hospitalised class II 0.26% 0.00%† 0.50%† β (α: 4.4, β: 1690) 13
When hospitalised class III 1.79% 0.69%† 3.04%† β (α: 9.0, β: 499) 13
When not hospitalised class III 0.67% 0.22%† 1.15%† β (α: 8.3, β: 1218) 13
When hospitalised class IV 5.33% 2.66%† 9.25%† β (α: 9.9, β: 175) 13
When not hospitalised class IV 0.72% 0.00%† 1.88%† β (α: 2.3, β: 319) 13
Utilities (quality of life)
After PCI (no heart failure) 0.86 0.85† 0.87† β (α: 2426, β: 395) 16
NYHA I 0.82 0.78† 0.85† β (α: 396, β: 90) 13
NYHA II 0.72 0.69† 0.75† β (α: 662, β: 257) 13
NYHA III 0.59 0.55† 0.63† β (α: 360, β: 250) 13
NYHA IV 0.51 0.41† 0.60† β (α: 52, β: 50) 13
Hospitalisation (decrement) −0.10 0.00* −0.20* β (α: 3.5, β: 31.5) 13
Costs per event
Myocardial infarction and PCI £4158 £83* £8233* γ (α: 4, β: 1223) 17
Cardioprotective agent £2500 £1000* £4000* Uniform (1000–4000) Assumption
Hospitalisation £1535 £96* £2974* γ (α: 4, β: 499) 17
Costs per month
Pharmaceutical therapy NYHA I £5 £3* £12* γ (α: 4, β: 0.50) 18, 19
Pharmaceutical therapy NYHA II £5 £3* £12* γ (α: 4, β: 0.50) 18, 19
Pharmaceutical therapy NYHA III £11 £7* £18* γ (α: 4, β: 1.00) 18, 19
Pharmaceutical therapy NYHA IV £15 £9* £22* γ (α: 4, β: 1.25) 18, 19
*Based on assumption.
†Based on 95% CI.
‡Using the methods described by Briggs et al.20
HF, heart failure; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
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reference cost schedule 2012/2013.17 The monthly costs
of the pharmaceutical treatment of HF were calculated
using information on drug use in the different NYHA
classes from a previous cost-effectiveness analysis19 and
applying 2014 National formulary unit prices.18 We
assumed that the drug would be administered at the
time of reperfusion and would not affect the length of
stay in the hospital or the need for diagnostic tests. For
the cost of a new cardioprotective agent we assumed a
one-off, one-time treatment of £2500 and because this is
a hypothetical agent, we varied this over a wide range
(£1000–£4000). Future costs and effects were discounted
at an annual rate of 3.5%.
Analysis
The main outcome of our analysis was the incremental
costs per quality-adjusted life-year (QALY) gained which
is the recommended cost-effectiveness measure for eco-
nomic evaluations in England.24 Because there are cur-
rently no data available on the effect and costs of a
cardioprotective agent, these parameters were varied
over a wide range. To assess the uncertainty of the
model we undertook several sensitivity analyses. First, all
parameters, such as the cost of a cardioprotective agent,
the cost of hospitalisation, the relative risk of HF with a
cardioprotective agent, the relative risk of mortality after
PCI with a cardioprotective agent, and the incidence of
HF after PCI were varied in a one-way sensitivity analysis.
Upper and lower limits were based on 95% CIs if avail-
able, otherwise assumptions about the range were made.
For some parameters, such as the ‘% of patients with HF
in each NYHA class’, when one value was changed in
the sensitivity analyses, the other values were changed
simultaneously so that the sum would always be 100%
(adding or subtracting the change in the parameter that
was tested from the largest category). Second, the price
and effect of a cardioprotective agent were varied simul-
taneously in a two-way sensitivity analysis to identify com-
binations of these values at which the ICER would be
below £20 000 per QALY gained. Lastly, a probabilistic
sensitivity analysis was carried out, drawing random
samples from the probability distributions of all para-
meters in 1000 simulations, using the distributions in
table 1. The proportion of times the ICER was less than
the cost-effectiveness threshold was calculated for
different values of the cost-effectiveness threshold,
ranging from £0 to £50 000, and presented graphically
using cost-effectiveness acceptability curves.
RESULTS
Base case
As shown in figure 2, the percentage patients without
HF decreased overtime, while the percentage of patients
with HF initially increased, but decreased after the first
year as more patients died. When a relative risk of 80%
was used for events in users of a cardioprotective agent,
the number of patients without HF was approximately
3% higher when a cardioprotective agent was used and
the number of patients with HF approximately 2%
lower. The percentage of patients who died was approxi-
mately 1% lower with a cardioprotective agent.
From the 1000 simulations, a 95% confidence range
could be calculated. The costs without use of a
cardioprotective agent ranged from £1793 to £10 963
(mean £5163) and QALYs ranged from 3.95 to 12.89
(mean 8.34). Patients lived on average 9.60 (SD: 2.39)
years after STEMI. With the use of a cardioprotective
agent, costs ranged from £3702 to £13 190 (mean £7498)
and QALYs from 4.01 to 13.12 (mean 8.52). Patients were
expected to live on average 9.77 (SD: 2.45) years after
STEMI. Incremental costs were £933 to £3820 (mean
£2334) and incremental QALYs 0.04 to 0.38 (mean 0.18).
The ICER ranged from £3311 to 63 480 per QALY
gained (mean £13 014). The results are summarised in
table 3.
Sensitivity analysis
As expected, the costs of a cardioprotective agent and
the relative risk of HF after PCI with a cardioprotective
agent had a large influence on the cost-effectiveness
results in our one-way sensitivity analysis. If the costs of a
cardioprotective agent would be £1000, the ICER would
be £4878, while if the costs would be £4000 the ICER
would be £22 004 per QALY gained. Other factors that
had a large influence on the ICER were age and relative
Table 2 Monthly transition probabilities among NYHA
class12–14
From↓
to→
NYHA I
(%)
NYHA II
(%)
NYHA III
(%)
NYHA IV
(%)
NYHA I 97.70 1.90 0.40 0.00
NYHA II 0.80 98.10 1.00 0.10
NYHA III 0.00 3.40 96.00 0.60
NYHA IV 0.00 0.00 5.50 94.50
Values were varied in the probabilistic sensitivity analysis using
Dirichlet distributions.20
NYHA, New York Heart Association.
Figure 2 Percentage of patients with or without HF or who
died. Solid line: no cardioprotection, dashed line: with
cardioprotective agent. HF, heart failure; PCI, percutaneous
coronary intervention.
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risk of mortality after PCI with a cardioprotective agent.
The ICER would exceed a threshold of £20 000 in
patients older than 70 and £30 000 in patients older
than 74. The effect of uncertainty around several key
parameters on the ICER is shown in the tornado
diagram in figure 3.
When the price and effect of a cardioprotective agent
were varied simultaneously we found that if the relative risk
of the cardioprotective agent would be 0.6 (preventing
40% of HF cases and mortality after PCI and also prevent-
ing 40% of new HF cases or worsening of HF in the follow-
ing 6 months) the price of the cardioprotective agent
could be as high as £6660 and still be below the £20 000
threshold. If the relative risk would only be 0.95, however,
the price should be no higher than £826. The results of
this two-way analysis are shown in figure 4. The incremental
cost-effectiveness ratios at various relative risk and cost
values are shown in online supplementary table S1.
In the probabilistic sensitivity analysis, the ICER was
below £20 000 per QALY gained in 71% of the simula-
tions. At a willingness-to-pay of £30 000 per QALY
gained, this probability would be 87%. The probability
that a cardioprotective agent would be cost-effective at
different thresholds is shown in figure 5.
DISCUSSION
In this study we have investigated the potential economic
consequences of a hypothetical cardioprotective agent.
The results of this study indicate that if a cardioprotec-
tive agent could be successfully developed for patients
with STEMI to decrease the risk of HF after PCI, it has a
high chance of being cost-effective. Currently there are
no such cardioprotective agents available, but it is
expected that this will change in the near future. In a
randomised trial of the cardioprotective effects of hypo-
thermia using cold saline and endovascular cooling the
incidence of HF was significantly lower in the hypother-
mia group than in the control group (3% vs 14%).25 In
this trial, no overall effect was shown on infarct size,
however, the infarct size was significantly smaller in the
subset of patients with anterior STEMI. In a small rando-
mised trial cyclosporine reduced infarct size,26 but this
effect could not be replicated in a more recent larger
trial.27 The antiplatelet drug abciximab reduced 30-day
infarct size when administered intravenously, but no sig-
nificant effect on HF was demonstrated.28 Intracoronary
administration of this drug did not result in a lower risk
of mortality or recurrent infarction, but did result in a
lower risk of new HF (2.4% vs 4.1%) compared to intra-
venous administration.29 The antidiabetic drug exena-
tide could also reduce infarct size, but only in those
reperfused early.30 31 In a recent trial, patients treated
with metoprolol before PCI had a smaller infarct size
and higher left ventricular ejection fraction.32 These
trials all suggest there are many potential cardioprotec-
tive agents that could affect the outcome of myocardial
infarction. Several reviews on this topic therefore
Table 3 Results (95% CIs) from the 1000 simulations
Costs (£) QALYs ICER (£/QALY)
No cardioprotection £5163 (1793 to 10 963) 8.34 (3.95 to 12.89)
Cardioprotective agent £7498 (3702 to 13 190) 8.52 (4.01 to 13.12)
Increment £2334 (933 to 3820) 0.18 (0.04 to 0.38) £13 014 (3311 to 63 480)
QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.
Figure 3 Tornado diagram
showing the effect of uncertainty
around the most influential
parameters on the incremental
cost-effectiveness ratio. HF, heart
failure; PCI, percutaneous
coronary intervention; QALY,
quality-adjusted life-year.
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conclude that it is likely that treatment of reperfusion
injury will become available in the near future.2–4
The economic burden of HF resulting from AMI has
been estimated to be at least £125–181 million to the
NHS and a further £27 million for nursing home costs
in 2000.33 The cost-effectiveness of treatment for post-
myocardial infarction HF was studied in several coun-
tries, such as the USA, Germany, the Netherlands,
France and Spain34 and also in the UK, where aldoster-
one antagonists were found to be a highly cost-effective
strategy for the management of HF.35 However, no
studies have been published up to this date on cardio-
protective agents to prevent HF in patients with AMI.
There was considerable uncertainty around many
input parameters in the model. This was caused by the
lack of specific data about the effectiveness and costs of
a cardioprotective agent (due to the hypothetical char-
acter of the study) or the small sample size of some
studies we used to predict variables in our analysis. We
accounted for this uncertainty by varying the parameters
over their 95% CIs or other (wide) plausible range in
the probabilistic sensitivity analysis. In this sensitivity
analysis we performed 1000 simulations to be able to cal-
culate CIs around our results.
The main limitation of this study is that it is based on
a hypothetical drug. There is currently not enough data
available on the long-term effectiveness of any of the
potential cardioprotective agents. We also assumed that
the cardioprotective agent would only reduce the risk
and severity of HF and not the risk of other clinical
major adverse cardiac events, such as recurrent infarc-
tion. In reality, a cardioprotective agent might have an
effect on all such events. However, by only taking into
account HF risk we present a conservative estimate of
the cost-effectiveness. A cardioprotective agent that will
also decrease the risk of other major adverse cardiac
events is expected to have a higher chance to be cost-
effective. Future studies should provide more data on
the long-term effectiveness of new agents, looking at
on-target as well as off-target effects and ideally also at
the quality of life. A strength of this study is that a model
is presented that can be used for any of the potential
cardioprotective agents to study the economic conse-
quences of implementing this agent in clinical practice.
If the effect of the new drug on the incidence of HF
after PCI is known, this model can be updated to
present a more precise estimate of the cost-effectiveness
of this drug. For this future research an update of the
estimates of relative risks for mortality and HF after PCI
is required and if applicable, other benefits of the treat-
ment can be added to the model.
The chance that a new cardioprotective agent will be
cost-effective mainly depends on the price of the agent,
the age of the patient and the relative risk of HF after
PCI. To be cost-effective a higher price for the drug
requires a greater effect on HF incidence or mortality.
At a price of £2500 and with a 20% reduction in HF
incidence and mortality after PCI, it is likely that the car-
dioprotective agent would be cost-effective.
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Figure 4 Results of the two-way sensitivity analysis. The
ICER would be higher than £20 000 per QALY gained in
scenarios represented by the light grey area, while the ICER
would be below this threshold in scenarios represented by the
dark grey area. ICER, incremental cost-effectiveness ratio;
QALY, quality-adjusted life-year.
Figure 5 Cost-effectiveness acceptability curve. QALY,
quality-adjusted life-year.
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